Drugs /

extended release flucytosine

Back to Drugs List

Overview

NCI Definition [1]:
An extended release (ER) oral tablet that contains flucytosine (5-FC), a fluorinated cytosine analog, with antifungal activity and potential anti-cancer activity. Following oral administration of ER 5-FC, the 5-FC is deaminated to its active metabolite 5-fluorouracil (5-FU). 5-FU replaces uracil during RNA synthesis, which consequently inhibits downstream protein synthesis. In addition, 5-FU is metabolized further to 5-fluorodeoxyuridylic acid monophosphate, which inhibits thymidylate synthetase. Inhibition of this enzyme interrupts nucleotide synthesis, DNA replication and cell proliferation. Negative regulation of protein synthesis, DNA replication and cell proliferation can lead to cell death. Following ingestion of ER 5-FC, intravenous injection of a retroviral vector encoding cytosine deaminase (TC 511) at a tumor site may result in higher local concentrations of 5-FU and its metabolites, and increased tumor cell death than other 5-FU treatment regimens.

Clinical Trials

View Clinical Trials for extended release flucytosine

Extended release flucytosine has been investigated in 2 clinical trials, of which 0 are open and 2 are closed. Of the trials investigating extended release flucytosine, 1 is phase 1 (0 open) and 1 is phase 2/phase 3 (0 open).

ABL2 Fusion, ACVR1B Loss, and ACVR1B Mutation are the most frequent biomarker inclusion criteria for extended release flucytosine clinical trials.

Anaplastic astrocytoma, bladder carcinoma, and breast carcinoma are the most common diseases being investigated in extended release flucytosine clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Extended Release Flucytosine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating extended release flucytosine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
extended-release flucytosine, extended-release 5-fluorocytosine, extended-release flucytosine, extended release 5-fc, extended release 5-fc, extended-release 5-fluorocytosine, extended release 5-fluorocytosine, toca fc, extended-release 5-fc, extended release 5-fluorocytosine, extended-release 5-fc
NCIT ID [1]:
C112498

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.